Swiss Biotech Day, first launched in 2021, will be held this year at Congress Center Basel on 4-5 May. 

The day provides a chance to explore advances in R&D, manufacturing, data management, AI and innovative financing. 

The 2026 Plenary Sessions will include a fireside session with Thomas Schinecker, CEO, Roche Group, and Patrick Amstutz, President of the Swiss Biotech Association on day one.  

On day two a highlight will be a keynote panel on the Swiss biotech ecosystem hosted by Patrick Amstutz, President of the Swiss Biotech Association, and featuring Alex Mayweg, MD, Versant Ventures; Luca Santarelli, CEO, Windward Bio; Mark Dawson, Head, Roche Pharma Research and Early Development (pRED); and Otello Stampacchia, Founder Omaga Ventures & Co-initiator of the European Life Science Coalition. 

The second day will also feature an investor panel entitled ‘Cross-Atlantic perspectives on Swiss biotech’, hosted by Seth Lewis, Executive Vice President Corporate Finance, Molecular Partners, with panellists: Andrew Hack, Bain Capital; Arjun Goyal, Vinyanshu Ventures; and Naveed Siddiqi, Novo Ventures. 

Swiss Biotech Day 2026 also offers: 

  • More than 3,000 senior experts from the life science industry 
  • More than 130 exhibitors and the Global Village with 25 international delegations from all over the world 
  • Over 50 thematic company pitching sessions and panel / round table discussions 
  • A dedicated 45‑minute poster session each day 
  • Pre-scheduled one-to-one partnering meetings 
  • General Assembly of the Swiss Biotech Association 

Registration is available now on the website. 

OECD data places Switzerland second in the world for biotechnology R&D intensity, and in 2021, the country had the seventh largest share of the global biotech market. A study conducted by IQVIA and published in the 2023 Swiss Biotech Report showed that 20% of European biotech companies are now headquartered in Switzerland. Read more about Swiss biotech.